FIRST-SIGN Wearable Cardiac Biomarker Testing at the Point of Need
- Coordinator
- Koc University, Türkiye
- Runs
- 1 August 2026 to 31 January 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335568
What the project is doing
In the project's own words, from its summary on CORDIS.
Every year, an estimated 2 million EU emergency ambulance transports for chest pain reach hospital without a single troponin measurement — the biomarker needed to confirm or rule out myocardial infarction (heart attack). After discharge, a substantial proportion of patients who develop post-infarction heart failure are rehospitalised within 30 days, with no tool to monitor troponin at home. This gap persists because troponin circulates at concentrations orders of magnitude lower than glucose, the required biofluids cannot be accessed without invasive sampling, and no minimally invasive wearable for troponin has yet been clinically validated for pre-hospital or home use.
FIRST-SIGN addresses these barriers using advances from the ERC Starting Grant 2ND-CHANCE (Grant No. 101043119). The parent grant developed aptamer-based troponin detection across the clinically relevant range and hollow microneedle arrays for minimally invasive interstitial fluid (ISF) extraction through the skin. FIRST-SIGN integrates these into a wearable patch that samples ISF via microneedles, measures cardiac troponin I (cTnI) with an aptamer-functionalised electrode, and is designed to return results to a smartphone within 10–20 minutes without a blood draw or trained operator.
During ambulance transport, the patch could provide clinicians with an early signal of cardiac injury; after discharge, it aims to let patients detect silent re-infarction at home before it becomes an emergency. Because the quantitative relationship between ISF and blood troponin remains poorly characterised, establishing this correlation is a central objective. Over 18 months, FIRST-SIGN will (1) adapt the biosensor for wearable operation, (2) benchmark ISF-derived troponin against venous blood in cardiac patients across cohorts, (3) build and usability-test an integrated prototype, and (4) define the regulatory and commercialisation pathway.
Success will position the device for CE marking and subsequent commercialisation in pre-hospital triage and post-discharge home cardiac monitoring.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Koc University | Istanbul | Türkiye | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI